(0.32%) 5 116.08 points
(0.31%) 38 357 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.41%) $2.03
(0.34%) $2 355.10
(0.56%) $27.69
(4.24%) $961.20
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis...
Stats | |
---|---|
本日の出来高 | 2.78M |
平均出来高 | 6.37M |
時価総額 | 8.18M |
EPS | $-0.0640 ( 2022-05-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.257 |
ATR14 | $0.131 (14.81%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-04-15 | Desparbes Eric | Buy | 231 693 | Common Stock |
2022-04-15 | Neumann Clarke | Buy | 184 843 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 2 transactions |
Buy: 416 536 | Sell: 0 |
ボリューム 相関
Progenity, Inc. 相関
10 最も負の相関 | |
---|---|
TBIO | -0.921 |
XPDI | -0.91 |
CCSI | -0.903 |
EYE | -0.898 |
WLTW | -0.897 |
PCAR | -0.896 |
ACHC | -0.882 |
JCOM | -0.868 |
ALHC | -0.863 |
FTXH | -0.858 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Progenity, Inc. 相関 - 通貨/商品
Progenity, Inc. 財務諸表
Annual | 2023 |
収益: | $4 000.00 |
総利益: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2023 |
収益: | $4 000.00 |
総利益: | $-551 000 (-13 775.00 %) |
EPS: | $-7.87 |
FY | 2022 |
収益: | $305 000 |
総利益: | $-602 000 (-197.38 %) |
EPS: | $-6.40 |
FY | 2021 |
収益: | $1.25M |
総利益: | $1.25M (100.00 %) |
EPS: | $-9.18 |
Financial Reports:
No articles found.
Progenity, Inc.
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。